

CURRICULUM VITAE

Date updated: 10/16/2013

PERSONAL INFORMATION:

Name: Matthew L. Stoll
Citizenship: U.S.A.

RANK / TITLE: Assistant Professor, Division of Pediatric Rheumatology 2011
Department: Pediatrics
Business address: University of Alabama at Birmingham
1601 4th Ave South
Birmingham, AL 35233
Phone: (205) 638-9438

HOSPITAL AND OTHER (NON-ACADEMIC) APPOINTMENTS:

Children's of Alabama (Birmingham, AL) 2011 – present
Childrens Medical Center (Dallas, TX) 2007 – 2011
Texas Scottish Rite Hospital for Children (Dallas, TX) 2007 – 2011

EDUCATION:

Wesleyan University (Middletown, CT) B.A. (Molec. Biology & Biochem.) 1994
[Graduated Phi Beta Kappa]
SUNY Upstate Medical University (Syracuse, NY) M.D., Ph.D. (Immunology) 2001
UT Southwestern Medical Center (Dallas, TX) M.S.C.S. 2011

LICENSURE:

New York (229888), inactive
Massachusetts (220256), inactive
Texas (M8363), inactive
Alabama (30926), active

BOARD CERTIFICATION:

2004 American Board of Pediatrics: General Pediatrics
2009 American Board of Pediatrics: Pediatric Rheumatology

POST-DOCTORAL TRAINING:

2001 – 2004 Residency in Pediatrics, Long Island Jewish Medical Center
2004 – 2007 Fellowship in Pediatric Rheumatology, Childrens Hospital Boston

ACADEMIC APPOINTMENTS:

2011 – present Assistant Professor, Department of Pediatrics, UAB, Birmingham, AL
2008 – 2011 Assistant Professor, Department of Pediatrics, UTSW, Dallas, TX
2007 – 2008 Instructor, Department of Pediatrics, UTSW, Dallas, TX

AWARDS / HONORS:

12/2012 Selected Member, Society for Pediatric Research
07/2004 Farley Fellowship Award (Childrens Hospital Boston; MA)

Matthew Stoll MD, PhD, MSCS

09/2000 Alpha Omega Alpha (SUNY Upstate Medical University; Syracuse, NY)
04/1994 Phi Beta Kappa (Wesleyan University; Middletown, CT)

PROFESSIONAL SOCIETIES:

2012 Society for Pediatric Research (SPR)
2012 UAB Comprehensive Arthritis, Musculoskeletal and Autoimmunity Center
2011 Alabama Society for Rheumatic Diseases (ASRD)
2010 Pediatric Rheumatology Collaborative Study Group (PRCSG)
2007 American College of Rheumatology (ACR)
2007 Childhood Arthritis and Rheumatology Research Alliance (CARRA)

MEMBERSHIPS:

(University of Alabama at Birmingham)

Comprehensive Arthritis, Musculoskeletal and Autoimmunity Center
Graduate Program in Immunology
Immunology, Autoimmunity and Transplantation (IAT) Committee
T Cell Biology Group

UNIVERSITY ACTIVITIES:

(UT Southwestern Medical Center)

1. Rheumatology Epic liason (2007 – 2011)

(University of Alabama at Birmingham)

2. Graduate Student Research Day, judge (2012)
3. Immunology, Allergy, and Transplant (IAT) committee member (2011 – present)

Clinical activities

1. Pediatric rheumatology outpatient clinic: three half-days per week.
2. Pediatric rheumatology inpatient consult service: 14 weeks per year

EDITORIAL BOARD MEMBERSHIPS:

Ad hoc reviewer for the following journals:

Arthritis Care and Research

Arthritis Research and Therapy

Clinical and Experimental Immunology

Journal of Rheumatology

Pediatrics

MAJOR RESEARCH INTERESTS:

My major research interest is the link between mucosal immunity and spondyloarthritis. Specifically, I am looking at the adaptive (humoral and T cell) immune responses to enteric organisms and the nature of the fecal flora in patients with spondyloarthritis. I also am interested in the epidemiology, diagnosis, and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA).

MENTORING EXPERIENCE:

Ph.D. review committee member: Miika Arvonon (University of Oulu, Finland) 2013

TEACHING EXPERIENCE:**Classroom instruction**

Fall 2011: Introduction to Clinical Medicine - I

Presentations

9/13/2012: Exploration of the microbiota in Inflammatory Diseases. Research Computing Day 2012, University of Alabama at Birmingham, AL.

06/15/2012: Adaptive immune responses to enteric microbiota in children with spondyloarthritis. Childrens Hospital Investigator Forum (CHIF), University of Alabama at Birmingham, AL.

03/28/2012: Collagen vascular diseases. Pediatric residents board review, University of Alabama at Birmingham, AL.

8/18/2010: Gut inflammation and arthritis. Gastroenterology noon conference, UTSW, Dallas, TX.

4/9/2010: Clinical research in pediatrics. Rheumatology fellow's conference, UTSW, Dallas, TX.

1/14/2010: Pediatric connective tissue diseases. Regional X Medical Conference for School-based PTs and OTs. Texas Scottish Rite Hospital, Dallas, TX.

5/29/2008: The risk of hospitalized infections in patients with rheumatoid arthritis. Rheumatology Journal Club, UT Southwestern Medical Center, Dallas, TX.

1/24/2008: Pain syndromes. Physical therapy in-service, Texas Scottish Rite Hospital for Children's Medical Center, Dallas, TX.

GRANT SUPPORT:

Current

Friends of CARRA

Enteric Flora in newly diagnosed spondyloarthritis: a collaborative study

Award dates 10/1/13 – 9/30/15

Role: Principal investigator

P60 AR064172 (Bridges, PI; Elson, PI, Project 3)

NIH / NIAMS

UAB Multidisciplinary Clinical Research Center – Project 3 (\$191,666 Annual Direct Costs)

Adaptive immune responses to gut microbiota in juvenile & adult spondyloarthritis

Award dates: 9/16/13 – 7/31/18

Role: Co-investigator

American College of Rheumatology – Rheumatology Research Foundation (ACR – RRF)

Exploration of the gut microbiome in spondyloarthritis

Award dates: 7/1/2013 – 6/30/2016

Role: Principal investigator

Kaul Pediatric Research Institute / Children's of Alabama

Identification of target antigens in children with spondyloarthritis

Award dates: 2/1/2013 – 1/31/2014

Role: Principal investigator

Previous

UAB School of Medicine: Immunology, Autoimmunity, and Transplant Strategic Effort

Autoimmunity against enteric antigens in juvenile spondyloarthritis

Award dates: 12/5/2011 – 12/31/2012

Role: Principal investigator

NIH/NCRR 1 KL2 RR024983-01

Principal Investigator: Packer, Milton

Project Title: North and Central Texas Clinical and Translational Science Initiative

Award Dates: 07/01/08 – present

Role: Clinical Sciences Trainee

NIH/NCRR 5 KL2 RR024983-02

Principal investigator: Packer, Milton

Award dates: 6/1/08 – 5/31/09

Role: pilot-award recipient PI

Subgroups of juvenile psoriatic arthritis: a clinical and gene expression analysis

UL1 RR024982-01

Principal investigator: Packer, Milton

Award dates: 9/17/07 – 6/30/08

North and Central Texas Clinical and Translational Science Initiative

Awardee: UT Southwestern Medical Center

Role: Clinical Sciences Trainee

T32-AI007512 Raif Geha (PI)

Award dates: 7/1/05 – 6/30/07

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants

Molecular Basis of Allergic and Immunologic Disease

Awardee: Childrens Hospital Boston

Role: Trainee.

BIBLIOGRAPHY:**PEER-REVIEWED MANUSCRIPTS:****Manuscripts already published**

1. Price K, Knupp CJ, Tatum AH, Jiang F, **Stoll ML**, Gavalchin J. Molecular identification of pathogenic Id^{LN}F₁ autoantibody idiotypes derived from the (NZB x SWR)F₁ model for systemic lupus erythematosus. *Journal of Autoimmunity* 2002; 19: 87-101.
2. **Stoll ML**, Listman JA. Nephrolithiasis in a neonate with transient renal wasting of calcium and magnesium. *Pediatric Nephrology* 2002; 17: 386-389.
3. Brown K, Ratner M, **Stoll M**. Pheochromocytoma unmasked by imipramine in an 8-year old girl. *Pediatric Emergency Care* 2003; 19: 174-177.
4. **Stoll ML**, Gauthier BG, Vergara M, Ramek J, Frank R, Trachtman H. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF. *Pediatric Nephrology* 2004; 19: 120-121.
5. **Stoll ML**, Rubin LG. Incidence of occult bacteremia among highly febrile young children presenting to a children's hospital emergency department or urgent care center in the era of the pneumococcal conjugate vaccine. *Archives of Pediatric and Adolescent Medicine* 2004; 158: 671-675.
6. **Stoll ML**, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. *Arthritis and Rheumatism* 2006; 54: 3564-3572.
7. **Stoll ML**, Price KD, Silvin CJ, Jiang F, Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR x NZB)F₁ murine model. *Journal of Autoimmunity* 2007; 29: 30-37.
8. **Stoll ML**, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for Rheumatology classification criteria for juvenile psoriatic arthritis. *Arthritis Care and Research* 2008; 59: 51-58.
9. **Stoll ML**, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA. TNF α inhibitors may improve asthma symptoms: a case series of

- 12 patients with rheumatoid arthritis and asthma. *Journal of Clinical Rheumatology* 2009; 15: 198-200.
10. Simard JF, **Stoll ML**, Shadick NA, Karlson EW, Solomon DH. Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity. *Journal of Clinical Epidemiology* 2010; 63: 1358-1362.
 11. **Stoll ML**, Bhole R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. *Journal of Rheumatology* 2010; 37: 2402-2408.
 12. **Stoll ML**, Nigrovic PA, Gotte AC, Punaro M. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. *Clinical and Experimental Rheumatology* 2011; 29: 582-588.
 13. **Stoll ML**, Li Q, Zhou J, Punaro M, Olsen N. Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course. *Clinical and Experimental Rheumatology* 2011; 29: 736-742.
 14. **Stoll ML**, Patel AS, Punaro M. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. *Journal of Rheumatology* 2011; 38: 2274-2275.
 15. **Stoll ML**, Patel AS, Punaro M, Dempsey-Robertson M. MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. *Pediatric Rheumatology* 2012; 10: 6.
 16. Feng F, Silvin C, Fiore N, **Stoll M**, Shanley P, Silverstone AE, and Gavalchin J. 17 β -Estradiol (E-2) administration to male (NZB x SWR)F1 mice results in increased IdLNF₁-reactive memory T-lymphocytes and accelerated glomerulonephritis. *Lupus*, 2012; 21: 288-301.
 17. **Stoll ML**, Patel AS, Christadoss ML, Punaro M, Olsen NJ. IgA transglutaminase levels in children with juvenile idiopathic arthritis. *Annals of Paediatric Rheumatology* 2012; 1: 31-35.
 18. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider, R, **Stoll ML**, Angeles-Han S, Milojevic D, Schikler KN, Vehe R, Weiss J, Weiss P, Ilowite N, Wallace C. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care and Research* 2012; 64: 1001-1010.
 19. **Stoll ML**, Good J, Sharpe T, Beukelman T, Young D, Waite PW, Cron RQ. Intraarticular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. *Journal of Oral and Maxillofacial Surgery* 2012; 70: 1802-1807.
 20. **Stoll ML**, Sharpe T, Beukelman T, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. *Journal of Rheumatology* 2012; 39: 1880-1887.
 21. Nyland JF, **Stoll ML**, Jiang F, Feng F, Gavalchin J. Mechanisms involved in the p62-73 idiotopeptide-modulated delay of lupus nephritis in SNF(1) mice. *Lupus* 2012; 21:1552-1564.
 22. **Stoll ML**, Morlandt A, Teerawattanapong S, Young D, Waite PD, Cron RQ. Safety and efficacy of intra-articular infliximab therapy for treatment resistant temporomandibular joint arthritis in children: a retrospective study. *Rheumatology* 2013; 52: 554-559.
 23. Henderson LA, Loring SL, Gill RR, Liao KP, Ishizawar R, Kim S, Perlmutter-Goldenson R, Rothman D, Son MB, **Stoll ML**, Zemel LS, Sandborg C, Dellaripa PF, Nigrovic PA. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. *Journal of Rheumatology* 2013; 40: 273-281.

Manuscripts in press

24. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, **Stoll ML**. High doses of infliximab in the management of juvenile idiopathic arthritis. *Journal of Rheumatology*, *in press*.
25. Vaid YN, Dunnivant DF, Royal SA, Beukelman T, **Stoll ML**, Cron RQ. Imaging of the temporomandibular joint in juvenile idiopathic arthritis. *Arthritis Care and Research*, *in press*.

Manuscripts submitted, but not yet in press

REVIEWS:

26. **Stoll M**, Gavalchin J. Systemic lupus erythematosus—messages from experimental models. *Rheumatology* 2000; 39:18-27.
27. **Stoll ML**, Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: a review of the literature. *Clinical and Developmental Immunology* 2006; 13): 377-380.
28. **Stoll ML**, Gotte AC. Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from adult and pediatric experiences. *Biologics: Targets and Therapies* 2008; 2(2): 229-252.
29. **Stoll ML**. Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. *Clinical and Experimental Rheumatology* 2011; 29: 322-330.
30. **Stoll ML**, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. *Current Opinion in Rheumatology* 2011; 23: 437-443.
31. **Stoll ML**, Cron RQ. Management of juvenile idiopathic arthritis in the biologic age. *Rheumatic Disease Clinics of North America*, in press.

BOOKS:

Book Chapters:

1. **Stoll ML**, Cron RQ. Inflammatory - juvenile idiopathic arthritis. IN: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms (1st edition). G. Siegal, T.S. Winokur, Eds., 2013, in press.

MAJOR LECTURES AND VISITING PROFESSORSHIPS:

11/12/2012: Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children. American College of Rheumatology Annual Scientific Meeting, concurrent abstract session: Washington, DC.

10/6/2012: Exploration of the Microbiota in Rheumatic Diseases. Lowe Conference 2012, Camp McDowell, AL.

10/13/2011: Juvenile Idiopathic Arthritis. Rheumatology Grand Rounds, University of Alabama at Birmingham, AL.

4/29/2011: Antibody Testing in the Evaluation of Rheumatic Diseases. 43rd Annual Kenneth C. Haltalin Pediatrics for the Practitioner conference, Richardson, TX.

12/7/2010: Mucosal Immunity In and Outcome of Spondyloarthritis. Rheumatology Grand Rounds, University of Alabama at Birmingham, AL.

9/30/2010: Kids Get Spondyloarthritis, Too! Rheumatology Grand Rounds, UTSW, Dallas, TX.

1/6/2009: Sub-clinical Gut Inflammation in Juvenile Spondyloarthritis. Department of Pediatrics Research Conference, UT Southwestern Medical Center, Dallas, TX.

12/18/2008: Juvenile Spondyloarthritis. Rheumatology Grand Rounds, UT Southwestern Medical Center, Dallas, TX.

4/15/2008: Subgroups within Oligo-articular JPsA and JIA: A Clinical and Gene Expression Analysis. Department of Pediatrics Research Conference, UT Southwestern Medical Center, Dallas, TX.

4/13/2007: Bone Marrow B-lineage Cells in RA Patients Treated with Rituximab. Pediatric Rheumatology Grand Rounds, Childrens Hospital Boston, MA.

12/15/2006: Role of aspirin in the prevention of thrombotic events in anti-phospholipid antibody-positive patients. Pediatric Rheumatology Grand Rounds, Childrens Hospital Boston, MA.

PUBLISHED ABSTRACTS

Poster presentations

1. **Stoll ML**, Price K, Silvin CJ, Gavalchin J. Idiotype-induced tolerance in a murine model of SLE. SLE Conference. November 5-8, 1997, National Institutes of Health, Washington, DC: Oral presentation
2. **Stoll ML**, Christadoss ML, Punaro M, Olsen NJ. MMP-3 and DKK-1 levels in juvenile idiopathic arthritis. *Arthritis and Rheumatism* 2010; 62: S621-622.
3. **Stoll M**, Punaro M, Dempsey-Robertson M. Gut inflammation in pediatric spondyloarthritis. *Arthritis and Rheumatism* 2010; 62: S94-95.
4. Cron RQ, Tambralli A, Beukelman T, Weiser P, Atkinson TP, **Stoll ML**. High doses of infliximab in the management of juvenile idiopathic arthritis. European League Against Rheumatism annual scientific meeting, Madrid, Spain. June 15, 2013. Abstract 13-3220.

Oral presentations

5. **Stoll ML**, Price K, Silvin CJ, Jiang F, Gavalchin J. Treatment of female (SWR x NZB)_{F1} mice with peptides derived from pathogenic autoantibodies delays the onset of murine lupus. Alpha Omega Alpha Research Conference. March 23, 1999, Upstate Medical University, Syracuse, NY: Oral presentation
6. **Stoll ML**, Rubin L. Are the CBC and blood culture necessary in the evaluation of febrile children 2-36 months of age in the Prevnar era? Nassau Pediatric Society, June 9, 2003, Carle Place, NY: Oral presentation
7. **Stoll ML**, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Clinical Immunology Society, March 17, 2006. Santa Fe, NM: Oral presentation (Matthew Stoll, presenter)
8. ILAR Criteria for juvenile psoriatic arthritis restrict inclusion without achieving clinical homogeneity. **Stoll ML**, Nigrovic PA, Sundel RP. American College of Rheumatology, November 14, 2006. Abstract # 2051. Washington, D.C.: Oral presentation (Matthew Stoll, presenter)
9. **Stoll ML**, Morlandt AB, Teerawattanaoing S, Young D, Waite PD, Cron RQ. Safety and efficacy of intraarticular infliximab therapy for treatment resistant temporomandibular joint arthritis in children. American College of Rheumatology, November 12, 2012. Abstract # 1677. Washington, D.C.: Oral presentation (Matthew Stoll, presenter)

VOLUNTEER WORK / COMMUNITY SERVICE:

10/13/2012: Lecturer, Juvenile Idiopathic Arthritis. JA Saturdays: Arthritis Foundation, Mobile, AL.

06/2013: Camp Physician, Camp MASH for children with rheumatic diseases, Camp Grace, Mobile, AL.

10/12/2013. Lecturer, Juvenile Idiopathic Arthritis. JA Saturdays: Arthritis Foundation, Birmingham, AL